Drug Profile
Research programme: ERN1 protein inhibitors - MannKind Corporation
Alternative Names: Inositol requiring enzyme-1 inhibitor; IRE-1α inhibitor; MKC 204; Mkc 8866; MKC-3946Latest Information Update: 28 Jul 2021
Price :
$50
*
At a glance
- Originator MannKind Corporation
- Class Antineoplastics; Small molecules
- Mechanism of Action ERN1 protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Multiple myeloma; Precursor cell lymphoblastic leukaemia-lymphoma
Most Recent Events
- 28 Jul 2021 No recent reports of development identified for preclinical development in Precursor-cell-lymphoblastic-leukaemia-lymphoma in USA
- 05 Dec 2020 Interim pharmacodynamics data from a preclinical study in in Precursor cell lymphoblastic leukaemia-lymphoma presented at the 62nd Annual Meeting and Exposition of the American Society of Hematology
- 22 Jun 2017 Preclinical trials in Acute lymphoblastic leukaemia in USA (unspecified route)